Here is the design of a clinical trial:

Official Title: A Randomized Double Blinded Within Dose, Controlled, Safety and Immunogenicity Study of GAS Vaccine Candidate in Healthy Individuals.

Included conditions:
- Group A Streptococcal Infection

Study Armgroups:
- {'label': 'Vaccine p*17-K4S2 (50 µg/mL) Vaccine', 'type': 'EXPERIMENTAL', 'description': 'To evaluate the safety and immunogenicity of p\\*17-CRM197 (25µg) + K4S2-CRM197 (6.25µg): TOTAL 31.25 µg', 'interventionNames': ['Biological: p*17-K4S2']}
- {'label': 'J8-K4S2 (100 µg/mL ) Vaccine', 'type': 'EXPERIMENTAL', 'description': 'To evaluate the safety and immunogenicity J8-CRM197 (50µg) + K4S2-CRM197 (6.25µg): TOTAL 56.25 µg', 'interventionNames': ['Biological: J8-K4S2']}
- {'label': 'Rabavert Vaccine', 'type': 'SHAM_COMPARATOR', 'description': 'Comparator vaccine (RABAVERT)', 'interventionNames': ['Biological: Rabavert vaccine']}

Interventions:
- {'type': 'BIOLOGICAL', 'name': 'p*17-K4S2', 'description': 'Administer p\\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly', 'armGroupLabels': ['Vaccine p*17-K4S2 (50 µg/mL) Vaccine']}
- {'type': 'BIOLOGICAL', 'name': 'J8-K4S2', 'description': 'Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly', 'armGroupLabels': ['J8-K4S2 (100 µg/mL ) Vaccine']}
- {'type': 'BIOLOGICAL', 'name': 'Rabavert vaccine', 'description': 'Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.', 'armGroupLabels': ['Rabavert Vaccine']}

Primary Outcomes:
- {'measure': 'Adverse Events', 'description': 'Safety is the primary outcome, and will be measured by assessing the clinical symptoms and signs at each study visit and completing standard lab parameters (hematological and biochemical) as well as performing echocardiograms to assess for mitral regurgitation', 'timeFrame': '6 months after last dose of vaccine is administered'}

Please estimate the sample size based on the assumption: 
A t-test with α = 0.05 and power = 0.8 was used for the sample size calculation.
Sample size {14}
        Thirty (30) participants are to be enrolledâ10 in J8-K4S2 arm, 10 in p*17-K4S2 arm, and 10 in comparator vaccine arm. This includes 10 patients in stage 1, for initial test doses, and 20 patients in stage 2, in a fully randomized, controlled stage (Fig. 1).
        To calculate this sample size, we took the J8-specific antibody titer as the continuous immunogenicity design endpoint and used data from a pilot study of the J8-DT vaccine in 8 healthy volunteers [20]. The mean (SD) titer of antibody to J8 was 1.6 (0.29) Î¼g/mL and 4.5 (2.4) Î¼g/mL at baseline and 28Â days after vaccination, respectively. Assuming the immunogenicity of the J8-K4S2 or p*17-K4S2 vaccine will be at least as strong, and using a t-test with Î±â=â0.05 and powerâ=â0.8, eight subjects per group would be needed to demonstrate an increase in titers after vaccination compared to commercial vaccine (RabAvert, by standard sample size calculations for normally distributed data.